This brand name is authorized in Estonia, Lithuania, Poland, United States
The drug UDENYCA contains one active pharmaceutical ingredient (API):
1
Pegfilgrastim
UNII 3A58010674 - PEGFILGRASTIM
|
Pegfilgrastim is a sustained duration form of filgrastim due to decreased renal clearance. Pegfilgrastim and filgrastim have been shown to have identical modes of action, causing a marked increase in peripheral blood neutrophil counts within 24 hours, with minor increases in monocytes and/or lymphocytes. |
Below package inserts are available for further reading:
Title | Information Source | Document Type | |
---|---|---|---|
UDENYCA Solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
ATC code | Group title | Classification |
---|---|---|
L03AA13 | Pegfilgrastim | L Antineoplastic and immunomodulating agents → L03 Immunostimulants → L03A Immunostimulants → L03AA Colony stimulating factors |
This drug has been assigned below unique identifiers within the countries it is being marketed:
Country | Identification scheme | Identifier(s) |
---|---|---|
Country: EE | Ravimiamet | Identifier(s): 1780499 |
Country: LT | Valstybinė vaistų kontrolės tarnyba | Identifier(s): 1086421 |
Country: PL | Rejestru Produktów Leczniczych | Identifier(s): 100411208 |
Country: US | FDA, National Drug Code | Identifier(s): 70114-101 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.